| Prev Close | 4.89 |
| Open | 4.97 |
| Day Low/High | 4.91 / 5.17 |
| 52 Wk Low/High | 3.10 / 11.93 |
| Volume | 86.75K |
Kindred Biosciences, Inc. (KIN)
5.20
0.31
6.30
NASDAQ
| Exchange | NASDAQ |
| Shares Outstanding | 39.37B |
| Market Cap | 199.99M |
| P/E Ratio | N/A |
| Div & Yield | N.A. (N.A) |
A Handful of Small Biotechs That Make for Merger Chatter
The names include a veterinary drug concern plus companies with successful drugs on the market.
2 Animal Drugmakers Worth a Sniff
Aratana Therapeutics and Kindred Biosciences are promising drug developers in the pet space.
The Final Fine-Tuned Gad Value Investment Portfolio for 2017
We've made a few tweaks due to price changes, while others were based on a last-minute assessment of better value.
The 2017 Gad Value Investment Fund, Part 2
The second half of our value-stocks portfolio for the New Year.
2 Bargains That Are Hiding in Plain Sight
Kindred Biosciences and GM may be 'too cheap not to own.'
Winning Value Portfolio Is Set to Beat the Market
Even if the markets were to take a dive, the strength of our holdings will prevail.
Good Stocks Can Come in Small Packages
These 3 names may not draw attention, but they can draw profits.
Value Portfolio Performs Well Amid Brexit Turmoil
A group of seven to 15 securities, if carefully selected, can provide all the diversification an investor needs.
It's Patient Capital's Time to Prosper
Brexit has caused active investors to flee and created an opportunity for those who are patient.
Portfolio Patience Is a Virtue
The energy rally is a good example.
Two Little Gems Are Hidden Amid Small-Caps
Sometimes, the under-research companies offer the biggest opportunities.
5 Picks for a Winning Value Portfolio, Part 2
Investors should see this selection as one part of a multi-year investment program.
As Calendar Year Dwindles, So Does Logic
Investors dump losing positions to start 'fresh' in 2016.
I Was Too Early to the Dance on Oil Stocks
My Winning Value Portfolio didn't live up to its name in 2015.
Winning Value Portfolio Is Anything But
August was a month to forget, dragged down by the energy names.
Winning Value Portfolio Taking a Hit
Despite portfolio performance, valuations of most of the stocks appear to be as compelling as ever.
Need for Patience Is Evident in Value Portfolio
Only Chenier Energy was a winner among these 10 names.
Value Portfolio Benefits From Patience
'Doing nothing' delivered in April.
Winning Value Portfolio Needs Patience
A weak March showing isn't catastrophic, but be ready for more pain.
A Winning Value Portfolio Update
Despite underperforming so far, the portfolio is well undervalued.
A Winning Value Portfolio Update
Off to a slow start, but time is still on our side in 2015.
2015 Gad Value Portfolio Revealed, Part 2
All that matters is valuation and potential upside.
Cheap Just Got Cheaper
A probabilistic biotech play.
Slim Pickings in Latest 13F Filings
Many value investors are making more concentrated bets.
Consider Drug Stocks for Animals
Bill Ackman is betting on Zoetis -- and you should, too.
Consider Adopting Kindred Biosciences
The stock's recent decline makes upside even more appealing.
You Can Ignore My Stock Picks
The 15% jump yesterday means little in my scheme of things.
Another Gem for the Biotech Basket
Amid the basket's impressive performance, I'm adding Minerva.
Profit From the Fed's Words
When the Fed knocks down certain market sectors, we value investors know what to do.
Building a Biotech Basket
Borrowing a page from a master investor's playbook.
